Free equity investment tool of Japanese companies

HOME >
Company List >
Mitsubishi Tanabe Pharma (Annual ): Financial Outline Report

Financial Outline Report: Annual; First quarter; Second quarter; Third quarter

Sponsored Link

Related Company: Nissan Chemical Industries; Kuraray; NIPPON KAYAKU; Sekisui Chemical; ROHTO PHARMACEUTICAL; 中外製薬; Aica Kogyo; TSUMURA & CO.; Mitsubishi Tanabe Pharma; NIHON NOHYAKU; キッセイ薬品工業; NIPPON PAINT; エスケー化研; ONO PHARMACEUTICAL; 大正製薬ホールディングス

EDIUNET Related Ranking: EDIUNET; EDIUNET Credit Rating; EDIUNET Industry Avg; EDIUNET Prefectures; Yuho! Industry

Prev « 2024-04 » Next

Mon	Tue	Wed	Thu	Fri	Sat	Sun
1 -	2 -	3 -	4 -	5 -	6 -	7 -
8 -	9 -	10 -	11 -	12 -	13 -	14 -
15 -	16 -	17 -	18 -	19 -	20 -	21 -
22 -	23 -	24 -	25 -	26 -	27 -	28 -
29 -	30 -

[Update list]

1/28 Retail Trade (CAWACHI:A etc...

1/27 Banks (The Awa Bank:BBB→A)

1/23 Chemicals (Milbon:AA→AAA)

1/21 Glass & Ceramics Products (..

1/21 Machinery (TSUDAKOMA:C)

1/21 Other Services (Netindex.:CC)

1/20 Other Products (Kurogane Kos..

1/20 Wholesale Trade (リーバイ・..

1/20 Other Services (川崎地質:BB→..

1/17 Chemicals (Kawaguchi Chemica..

RSS

Company RSS

Daily RSS

Sponsored Link

Recently Download Chart: NIPPON COKE & ENGINEERING

Yushiro Chemical Indutry

Nittetsu Mining

メルコホールディングス

日本アビオニクス

Financial Outline Report: Mitsubishi Tanabe Pharma (Annual )

It is a free Financial Outline Report which can grasp intuitively a financial statement summary , a corporate value, credit rating, etc. by various charts.Two or more companies can be compared and various charts can also be downloaded.

【Analysis Menu】 Outline Statement Rating Indicator Download

Summary: Mitsubishi Tanabe Pharma (Annual )

Credit Rating (Bankruptcy Risk) Consolidated | Non-Consolidated

Date	Credit Rating	Comment	Sales	Current Profit	Net Income
2013-03-31	A	Credit is high, but affected by biz environs.	¥ 419 B 2.95%	¥ 69 B 0.92%	¥ 41 B 7.37%

Financial Timeline

Date	2012-12-31 (Third quarter )	2013-03-31 (Annual )	2013-06-30 (First quarter )	2013-09-30 (Second quarter )
Credit Rating	A	A	B	A
Total Assets	¥ 845 B	¥ 866 B	¥ 853 B	¥ 881 B
Net Assets	¥ 733 B	¥ 752 B	¥ 753 B	¥ 767 B

Net income has increased 5 consecutive terms. The performance is good.

Net Assets have increased 5consecutive terms. The fiscal base is getting better.

Date	Credit Rating	Comment	Sales	Current Profit	Net Income
2013-03-31	A	Credit is high, but affected by biz environs.	¥ 396 B 1.89%	¥ 76 B 9.47%	¥ 54 B 23.06%

Date	- (First quarter )	- (Second quarter )	- (Third quarter )	2013-03-31 (Annual )
Credit Rating	-	-	-	A
Total Assets	-	-	-	¥ 730 B
Net Assets	-	-	-	¥ 615 B

Financial Chart Download

Financial Timeline Chart

Financial Statement Details

Indicator Comparison Chart

Financial Indicator Details

Profitability	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Net profit margin (Industry Average)	6.39% (-12.05%)	7.47% (-0.50%)	9.21% (1.53%)	9.58% (-1.67%)	9.99% (3.05%)
C/F margin (Industry Average)	12.18% (-3.31%)	5.91% (8.51%)	14.42% (7.04%)	9.14% (6.35%)	14.45% (8.25%)
ROA (Industry Average)	3.27% (0.52%)	3.79% (1.04%)	4.61% (2.07%)	4.75% (0.06%)	4.83% (2.71%)
ROE (Industry Average)	3.98% (-1.43%)	4.46% (0.03%)	5.42% (2.96%)	5.40% (4.68%)	5.56% (4.57%)
Growth	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Equity growth (Industry Average)	- (-)	1.59% (5.01%)	2.82% (2.61%)	3.66% (-0.40%)	4.35% (8.16%)
Sales growth (Industry Average)	- (-)	-2.41% (-2.67%)	1.18% (5.36%)	-0.58% (1.07%)	2.95% (2.24%)
Net profit growth (Industry Average)	- (-)	14.02% (203.46%)	24.77% (63.25%)	3.35% (3.89%)	7.37% (90.38%)
Operating C/F growth (Industry Average)	- (-)	-52.66% (275.10%)	146.90% (35.09%)	-36.94% (-6.09%)	62.66% (138.39%)
Stability	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Capital adequacy (Industry Average)	82.17% (53.80%)	84.93% (54.51%)	85.00% (55.00%)	87.99% (53.59%)	86.86% (56.30%)
Liquidity ratio (Industry Average)	408.79% (217.72%)	442.66% (225.70%)	446.38% (237.55%)	603.08% (239.89%)	553.52% (236.21%)
C/F ratio current liabilities (Industry Average)	176.39% (777.21%)	325.07% (303.31%)	148.51% (434.79%)	186.81% (929.73%)	142.13% (573.30%)
Quick ratio (Industry Average)	170.56% (138.97%)	191.62% (148.85%)	177.58% (156.17%)	205.03% (160.84%)	174.35% (156.81%)
Turnover	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Receivables turnover (Industry Average)	112.76day (83.89day)	113.83day (94.27day)	114.41day (93.96day)	114.03day (97.92day)	113.08day (98.27day)
Inventory turnover (Industry Average)	68.37day (54.45day)	65.98day (52.58day)	69.25day (52.64day)	77.26day (56.59day)	80.79day (58.68day)
Payable turnover (Industry Average)	22.96day (45.01day)	24.85day (49.82day)	26.39day (49.52day)	25.88day (52.10day)	33.15day (51.12day)
Working capita turnover (Industry Average)	158.16day (93.32day)	154.96day (97.02day)	157.26day (97.08day)	165.41day (102.41day)	160.72day (105.83day)
Stock etc.	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Market Value growth (Industry Average)	- (-)	35.94% (34.57%)	2.27% (1.49%)	-14.00% (-3.85%)	24.46% (21.16%)
Dividend Yield (Industry Average)	2.77% (3.20%)	2.12% (1.93%)	2.07% (2.17%)	2.49% (2.45%)	2.76% (2.07%)
PER (Industry Average)	20.54% (25.22%)	24.49% (23.06%)	20.07% (16.22%)	16.70% (29.19%)	19.36% (16.58%)
PBR (Industry Average)	0.81% (0.86%)	1.09% (1.06%)	1.08% (1.04%)	0.90% (0.95%)	1.07% (1.08%)
PCFR (Industry Average)	10.78% (7.18%)	30.97% (9.23%)	12.83% (-2.43%)	17.49% (9.50%)	13.38% (7.56%)
PSR (Industry Average)	1.31% (0.77%)	1.83% (0.88%)	1.85% (1.10%)	1.60% (0.90%)	1.93% (1.01%)

Profitability	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Net profit margin (Industry Average)	8.64% (-27.66%)	11.06% (-4.34%)	12.84% (-5.37%)	11.40% (-10.69%)	13.76% (8.92%)
C/F margin (Industry Average)	- (0.87%)	- (1.04%)	- (0.82%)	- (-0.81%)	- (-39.63%)
ROA (Industry Average)	5.17% (0.52%)	6.76% (0.92%)	7.55% (1.42%)	6.58% (-0.27%)	7.47% (1.53%)
ROE (Industry Average)	6.59% (-0.84%)	8.31% (-0.46%)	9.23% (1.81%)	7.71% (3.42%)	8.86% (2.62%)
Growth	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Equity growth (Industry Average)	- (-)	6.36% (3.64%)	5.80% (3.03%)	6.02% (0.04%)	7.04% (3.91%)
Sales growth (Industry Average)	- (-)	4.88% (-3.48%)	1.20% (6.70%)	-0.28% (0.75%)	1.89% (-1.74%)
Net profit growth (Industry Average)	- (-)	34.12% (166.48%)	17.48% (43.48%)	-11.46% (-47.04%)	23.06% (62.14%)
Operating C/F growth (Industry Average)	- (-)	- (89.80%)	- (77.44%)	- (-44.41%)	- (46.89%)
Stability	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Capital adequacy (Industry Average)	78.38% (56.79%)	81.27% (57.65%)	81.80% (57.17%)	85.34% (55.93%)	84.27% (57.57%)
Liquidity ratio (Industry Average)	349.06% (337.22%)	350.45% (276.75%)	357.19% (266.94%)	463.97% (314.47%)	448.54% (233.84%)
C/F ratio current liabilities (Industry Average)	- (48.90%)	- (53.10%)	- (31.35%)	- (76.77%)	- (31.87%)
Quick ratio (Industry Average)	139.44% (167.28%)	152.75% (183.78%)	143.23% (174.83%)	159.54% (228.06%)	134.79% (169.77%)
Turnover	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Receivables turnover (Industry Average)	117.42day (87.55day)	117.03day (98.39day)	118.17day (95.88day)	117.35day (98.58day)	117.14day (67.18day)
Inventory turnover (Industry Average)	43.91day (50.17day)	42.31day (48.43day)	45.12day (47.43day)	46.86day (50.67day)	53.31day (38.21day)
Payable turnover (Industry Average)	31.18day (45.70day)	33.05day (51.63day)	33.87day (51.13day)	31.38day (53.57day)	37.53day (34.24day)
Working capita turnover (Industry Average)	130.15day (92.02day)	126.28day (95.19day)	129.42day (92.19day)	132.84day (95.69day)	132.92day (71.15day)
Stock etc.	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Market Value growth (Industry Average)	- (-)	35.94% (34.46%)	2.27% (3.11%)	-14.00% (-3.30%)	24.46% (24.19%)
Dividend Yield (Industry Average)	- (0.15%)	- (0.09%)	- (0.10%)	- (0.16%)	- (0.15%)
PER (Industry Average)	17.14% (34.12%)	17.37% (27.80%)	15.12% (13.58%)	14.69% (22.26%)	14.85% (26.42%)
PBR (Industry Average)	1.13% (0.97%)	1.44% (1.21%)	1.39% (1.17%)	1.13% (1.08%)	1.31% (1.54%)
PCFR (Industry Average)	- (0.27%)	- (0.62%)	- (0.23%)	- (0.08%)	- (4.97%)
PSR (Industry Average)	1.48% (3.42%)	1.92% (4.34%)	1.94% (3.67%)	1.67% (4.37%)	2.04% (10.14%)

Corporate value chart

Enterprise Value	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Market Value	¥ 545 B (1)	¥ 741 B (1)	¥ 757 B (1)	¥ 651 B (1)	¥ 811 B (1)
Net Value	¥ 666 B (0.82)	¥ 676 B (1.09)	¥ 695 B (1.09)	¥ 721 B (0.9)	¥ 752 B (1.08)
Returns Value	¥ 446 B (1.22)	¥ 492 B (1.51)	¥ 545 B (1.39)	¥ 554 B (1.18)	¥ 539 B (1.5)
Dividend Value	¥ 255 B (2.14)	¥ 255 B (2.9)	¥ 227 B (3.34)	¥ 231 B (2.82)	¥ 288 B (2.81)
Enterprise Value	¥ 528 B (1.03)	¥ 720 B (1.03)	¥ 733 B (1.03)	¥ 638 B (1.02)	¥ 792 B (1.02)

Enterprise Value	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Market Value	¥ 545 B (1)	¥ 741 B (1)	¥ 757 B (1)	¥ 651 B (1)	¥ 811 B (1)
Net Value	¥ 482 B (1.13)	¥ 512 B (1.45)	¥ 542 B (1.4)	¥ 575 B (1.13)	¥ 615 B (1.32)
Returns Value	¥ 535 B (1.02)	¥ 559 B (1.33)	¥ 563 B (1.35)	¥ 632 B (1.03)	¥ 695 B (1.17)
Dividend Value	- (- )	- (- )	- (- )	- (- )	- (- )
Enterprise Value	¥ 534 B (1.02)	¥ 728 B (1.02)	¥ 741 B (1.02)	¥ 646 B (1.01)	¥ 806 B (1.01)

Related Information: Mitsubishi Tanabe Pharma (Annual )

Statement Type: Annual : Mitsubishi Tanabe Pharma; First quarter : Mitsubishi Tanabe Pharma; Second quarter : Mitsubishi Tanabe Pharma; Third quarter : Mitsubishi Tanabe Pharma

Analysis Menu: Outline : Mitsubishi Tanabe Pharma; Statement : Mitsubishi Tanabe Pharma; Rating : Mitsubishi Tanabe Pharma; Indicator : Mitsubishi Tanabe Pharma; Download : Mitsubishi Tanabe Pharma

Industry Comparison Ranking: Chemicals - EDIUNET Industry Rankings; Chemicals - EDIUNET Credit Rating; Chemicals - EDIUNET Industry Avg

Comparison with a neighboring company: Osaka - EDIUNET Prefectures; Osaka大阪市 - EDIUNET Prefectures

Related company's newest statement

Date	Company	Credit Rating	Date
1/23	Milbon	AA→AAA	2013-12-20
1/17	Kawaguchi Chemical Indu..	BBB→BB	2013-11-30
1/17	SANKEI CHEMICAL	A	2013-11-30
1/15	HOKKO CHEMICAL INDUSTRY	BB→B	2013-11-30
1/15	Daito Pharmaceutical Co .	AA	2013-11-30 (Q2)
1/15	KAWAKAMI PAINT MFG.	B→BB	2013-11-30
1/15	旭化学工業	AA	2013-11-30 (Q1)
1/10	OSAKA ORGANIC CHEMICAL ..	BB→BBB	2013-11-30
1/10	HISAMITSU PHARMACEUTICAL	A	2013-11-30 (Q3)
1/10	AMS Life Science	BBB→BB	2013-11-30 (Q1)

EDIUNET Investment News (Chemicals): 1/23 Chemicals (Milbon:AA→AAA); 1/17 Chemicals (Kawaguchi Chemica..; 1/15 Chemicals (HOKKO CHEMICAL IN..; 1/10 Chemicals (OSAKA ORGANIC CHE..; 1/9 Chemicals (SANKO GOSEI:A); 12/27 Chemicals (Niitaka:A); 12/18 Chemicals (KUMIAI CHEMICAL I..; 12/12 Chemicals (IHARA CHEMICAL IN..; 12/11 Chemicals (Konoshima Chemica..; 12/10 Chemicals (NATOCO:AA)

EDIUNET Caution

*Financial data might be different from the actual one. Please confirm the original, and read Caution.

*This site has obtained the information from the FSA's EDINET, Tokyo Stock Exchange's TDnet and Pay statistical data services, Fukuoka stock Exchange's Stock market capitalization, Center for Spatial Information Science's CSV Geocoding Service. The copyright of the information belongs to each corporation etc. .

▲ Go to the top ▲

HOME >
Company List >
Mitsubishi Tanabe Pharma (Annual ): Financial Outline Report

EDIUNET Rating News

Screening Search

Member limited service

Company Search
- [close]
  
  [keyword]
  
  Company Search
  
  *It can search to each item of a type of industry, a stock market, the settlement-of-accounts moon, and a keyword.
  
  *Top 30 search results are displayed.
  
  [close]

Company Ranking

Free equity investment tool of Japanese companies

Financial Outline Report: Mitsubishi Tanabe Pharma (Annual )

Summary: Mitsubishi Tanabe Pharma (Annual )

Credit Rating (Bankruptcy Risk) Consolidated | Non-Consolidated

Financial Timeline

Credit Rating (Bankruptcy Risk) Consolidated | Non-Consolidated

Financial Timeline

Financial Chart Download

Financial Timeline Chart

Indicator Comparison Chart

Consolidated :Indicator Consolidated | Non-Consolidated

Non-Consolidated :Indicator Consolidated | Non-Consolidated

Corporate value chart

Related Information: Mitsubishi Tanabe Pharma (Annual )

Related company's newest statement

Related Company

関連する株式投資情報

EDIUNET Caution